Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Dasatinib (Sprycel®) is an orally administered, small molecule inhibitor of multiple tyrosine
kinases. In the phase 3 DASISION trial, dasatinib 100 mg once daily resulted in deeper and …

Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal
chromosomal translocation between chromosomes 9 and 22 [t (9; 22)], producing the Bcr …

In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib,
we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell …

BACKGROUND: Dasatinib, a highly potent BCR‐ABL inhibitor, is an effective treatment for
patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance …

Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic
myeloid leukemia (CML), which provides an identifiable target for developing therapeutic …

Deregulated activity of the Src tyrosine kinases leads to malignant transformation. Since the
FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic …

Tyrosine kinase inhibitors (TKIs) have potent effects on malignant cells, and they also target
kinases in normal cells, which may have therapeutic implications. Using a collection of 55 …